RecruitingPhase 3NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Sponsor: Merck Sharp & Dohme LLC
Buffalo, NY · East Syracuse, NY · New York, NY · +51 more sites